Novartis files oral MS drug fingolimod in US and EU
21 January 2010
Katie McQue
Please Login to read the full article.
21 January 2010
Katie McQue
Novartis has filed its once-daily oral multiple sclerosis therapy fingolimod (also known as FTY720) in the US and EU for the treatment of the most common relapsing-remitting form of the disease.
Fingolimod is battling with Merck Serono's Cladribine tablets to become the first...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novartis' new Gilenya data fails to address NICE concerns as final decision looms
- Novartis' Gilenya works regardless of treatment history, says new report
- A year in pharma and biotech R&D: Healthy numbers belie lack of novelty
- 7th Annual Scrip Awards: Novartis, Jimenez, Burrill, Glenmark, ICON win
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
